Caribou Biosciences (NASDAQ:CRBU) Issues Earnings Results, Beats Estimates By $0.06 EPS

Caribou Biosciences (NASDAQ:CRBU) posted its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06, Zacks reports. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 43.47%. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million.

Caribou Biosciences Stock Down 3.6 %

Shares of NASDAQ:CRBU traded down $0.10 during midday trading on Friday, hitting $2.68. 2,467,955 shares of the stock traded hands, compared to its average volume of 1,257,875. The stock has a market capitalization of $242.16 million, a PE ratio of -1.62 and a beta of 2.26. Caribou Biosciences has a one year low of $1.50 and a one year high of $8.33. The business’s 50 day moving average is $2.01 and its two-hundred day moving average is $2.30.

Analyst Ratings Changes

A number of research firms have recently weighed in on CRBU. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $14.00 price objective on shares of Caribou Biosciences in a research report on Wednesday, August 7th.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.